{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:03:47Z","timestamp":1793862227912,"version":"4.6.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Vaccinations have had a transformative impact on public health, reducing the incidence of many infectious diseases and increasing survival. However, there remains uncertainty about the potential of vaccines to trigger autoimmune diseases such as the idiopathic inflammatory myopathies (IIM). Myositis after vaccination (MAV) is a rare clinical entity, but given immunogenetic associations with other adverse events, we explored genetic risk factors, particularly human leukocyte antigen (HLA) alleles and GM\/KM immunoglobulin allotypes, that may predispose individuals to develop MAV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We examined clinical characteristics, vaccination history, autoantibodies, HLA alleles and GM\/KM allotypes from 56 patients who developed MAV, 133 myositis cases with no documented vaccination within 6 months of onset (non-MAV), and 527 healthy controls from the pre-COVID-19 era. Genotyping for HLA and GM\/KM allotypes was performed by standard assays. Differences in allele frequencies in race-matched groups were evaluated using chi-square tests, odds ratios (OR) and 95% confidence intervals (CI). Multivariate logistic regression adjusted for age, sex, and vaccination type. Statistical significance was defined as a Holms corrected p-value of less than 0.05.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No clinical or serologic differences were found between MAV and non-MAV patients. However, the HLA-DQA1*03:03 allele was a unique risk factor for MAV in Caucasians (OR=3.87, 95% CI=1.56-9.54, p=0.002), while the known myositis risk factor, HLA-DRB1*03:01, was a protective factor for MAV (OR=0.41, 95% CI=0,18-0.94, p= 0.033). GM2, GM13, and KM1 allotypes were more frequently observed in MAV patients than healthy controls, and other HLA alleles were risk or protective factors for specific vaccines given in patients who developed MAV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Immunogenetic factors may influence the likelihood of developing MAV. Further studies of larger, deeply phenotyped populations are needed to confirm these associations and could inform personalized risk assessments and targeted interventions, thereby enhancing vaccine safety.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1539659","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:27:49Z","timestamp":1755235669000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["A possible role for immunogenetic factors in myositis developing after vaccination in the pre-covid-19 era"],"prefix":"10.3389","volume":"16","author":[{"given":"Eaman","family":"Alhassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ejaz A.","family":"Shamim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janardan P.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2018.48","article-title":"Risk factors and disease mechanisms in myositis","volume":"14","author":"Miller","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2021.03.009","article-title":"A catalog of GWAS fine-mapping efforts in autoimmune disease","volume":"108","author":"Caliskan","year":"2021","journal-title":"Am J Hum Genet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25423","article-title":"Environment, lifestyles, and climate change: the many nongenetic contributors to the long and winding road to autoimmune diseases","volume":"77","author":"Miller","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2174\/1871528114666160105113046","article-title":"Vaccination and induction of autoimmune diseases","volume":"14","author":"Toussirot","year":"2015","journal-title":"Inflammation Allergy Drug Targets"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e15178","DOI":"10.1111\/1756-185X.15178","article-title":"Characteristics of emerging new autoimmune diseases after COVID-19 vaccination: A sub-study by the COVAD group","volume":"27","author":"Shumnalieva","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-091212-153450","article-title":"Mapping of immune-mediated disease genes","volume":"14","author":"Rica\u00f1o-Ponce","year":"2013","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208119","article-title":"Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups","volume":"75","author":"Rothwell","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2015.28","article-title":"Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes","volume":"16","author":"Miller","year":"2015","journal-title":"Genes Immun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3109\/08916939508995322","article-title":"Immunoglobulin allotypes (GM and KM) and their interactions with HLA antigens in autoimmune diseases: a review","volume":"22","author":"Dugoujon","year":"1995","journal-title":"Autoimmunity"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/art.23899","article-title":"Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies","volume":"58","author":"O\u2019Hanlon","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)90761-4","article-title":"Dermatomyositis and vaccination","volume":"1","author":"Ehrengut","year":"1978","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92325-5","article-title":"Dermatomyositis after immunisation","volume":"2","author":"Cotterill","year":"1978","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(78)90885-1","article-title":"Dermatomyositis after B.C.G. vaccination","volume":"1","author":"K\u00e5ss","year":"1978","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3109\/03009747909114454","article-title":"Dermatomyositis associated with BCG vaccination","volume":"8","author":"K\u00e5ss","year":"1979","journal-title":"Scand J Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1972.02110070103015","article-title":"Dermatomyositis with cerebral vasculitis in a patient with agammaglobulinemia","volume":"123","author":"Gotoff","year":"1972","journal-title":"Am J Dis Child"},{"key":"B16","article-title":"Infantile dermatomyositis. Study of 8 personal cases","volume":"14","author":"Thieffry","year":"1967","journal-title":"Ann Pediatr (Paris)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(64)80325-5","article-title":"DERMATOMYOSITIS","volume":"64","author":"Bitnum","year":"1964","journal-title":"J Pediatr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311429557","article-title":"Macrophagic myofasciitis: characterization and pathophysiology","volume":"21","author":"Gherardi","year":"2012","journal-title":"Lupus"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2343","article-title":"Immunopharmacogenomics: mechanisms of HLA-associated drug reactions","volume":"110","author":"Deshpande","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.20587","article-title":"Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops","volume":"50","author":"O\u2019Hanlon","year":"2004","journal-title":"Arthritis Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247563","article-title":"Post-COVID-19 and post-COVID-19 vaccine arthritis, polymyalgia rheumatica and horton\u2019s arteritis: A single-center assessment of clinical, serological, genetic, and ultrasonographic biomarkers","volume":"12","author":"Bandinelli","year":"2023","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000217525.82287.eb","article-title":"Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies","volume":"85","author":"O\u2019Hanlon","year":"2006","journal-title":"Med (Baltimore)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.100.2.274","article-title":"A new rapid method for genetic typing of human immunoglobulins","volume":"100","author":"Vyas","year":"1968","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B27","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure","volume":"6","author":"Holm","year":"1979","journal-title":"Scand J Stat"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13448","article-title":"The role of environmental exposures and gene-environment interactions in the etiology of systemic lupus erythematous","volume":"291","author":"Woo","year":"2022","journal-title":"J Intern Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000149765.71212.0A","article-title":"The HLA locus and multiple sclerosis in Sicily","volume":"64","author":"Brassat","year":"2005","journal-title":"Neurology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1371\/journal.pgen.0030192","article-title":"Identification of two independent risk factors for lupus within the MHC in United Kingdom families","volume":"3","author":"Fernando","year":"2007","journal-title":"PloS Genet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/art.27426","article-title":"Analysis of maternal-offspring HLA compatibility, parent-of-origin effects, and noninherited maternal antigen effects for HLA-DRB1 in systemic lupus erythematosus","volume":"62","author":"Bronson","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)91201-X","article-title":"HL-A antigens and diabetes mellitus","volume":"2","author":"Nerup","year":"1974","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2337\/diab.40.4.478","article-title":"Implication of specific DQB1 alleles in genetic susceptibility and resistance by identification of IDDM siblings with novel HLA-DQB1 allele and unusual DR2 and DR1 haplotypes","volume":"40","author":"Erlich","year":"1991","journal-title":"Diabetes"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.10.002","article-title":"HLA and Sj\u00f6gren\u2019s syndrome susceptibility. A meta-analysis of worldwide studies","volume":"11","author":"Cruz-Tapias","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1973.00490210082014","article-title":"Vasculitis and myositis secondary to rubella vaccination","volume":"28","author":"Hanissian","year":"1973","journal-title":"Arch Neurol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/0264-410X(94)90166-X","article-title":"Influenza vaccine and dermatomyositis","volume":"12","author":"Jani","year":"1994","journal-title":"Vaccine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-007-0485-4","article-title":"HBV vaccine and dermatomyositis: is\u00a0there an association","volume":"28","author":"Altman","year":"2008","journal-title":"Rheumatol Int"},{"key":"B38","doi-asserted-by":"publisher","first-page":"836930","DOI":"10.1155\/2012\/836930","article-title":"Polymyositis following pandemic influenza A (H1N1) and 2009\u201310 seasonal trivalent vaccines","volume":"2012","author":"Ferri","year":"2012","journal-title":"Case Rep Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008151","article-title":"Severe\u00a0acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination","volume":"12","author":"Watson","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/acr.25236","article-title":"Dermatomyositis in association with SARS-coV-2 infection or COVID-19 vaccine","volume":"76","author":"Diaz-Menindez","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"105136","DOI":"10.1016\/j.ebiom.2024.105136","article-title":"MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C)","volume":"104","author":"David","year":"2024","journal-title":"EBioMedicine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1539659\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:27:49Z","timestamp":1755235669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1539659\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2025.1539659"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1539659","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"article-number":"1539659"}}